FDA Approves New Vaccines and Treatments in 2024

In response to rising Lyme disease cases, Pfizer and Valneva are conducting a phase 3 clinical trial for the VLA15 vaccine. The FDA has also made significant strides in 2024, approving the first mRNA cancer vaccine for Epstein-Barr virus, alongside new vaccines for various diseases amidst rising COVID-19 cases. Misinformation has proliferated in the lead-up to numerous elections, with a report indicating that 71% of Europeans face frequent disinformation, raising concerns about its impact on democracy. Meanwhile, discussions around pediatric COVID-19 mRNA vaccines have intensified following the tragic death of a 10-month-old baby, sparking debates over vaccine safety. The year's health landscape has been dominated by issues surrounding new medications and the ongoing threat of infectious diseases, while misinformation remains a critical concern for voters worldwide. As we move into 2025, the implications of these health and political challenges are expected to resonate further.